Interleukin (IL)-17 is the founding member of a novel family of inflammatory cytokines. While the pro-inflammatory properties of IL-17 are key to its host-protective capacity, unrestrained IL-17 signaling is associated with immunopathology, autoimmune disease and cancer progression. In this review, we discuss both the activators and the inhibitors of IL-17 signal transduction, and the physiological implications of these events. We highlight the surprisingly diverse means by which these regulators control expression of IL-17-dependent inflammatory genes, as well as the major target cells that respond to IL-17 signaling.